Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM041IZ)

Drug Name

GED-aPC Drug Info

Synonyms

LY458202; LY-458202

Indication

Disease Entry	ICD 11	Status	REF
Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Vitamin K-dependent protein C (PROC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sodium Tetradecyl Sulfate	DM4QFXJ	Hemangioma	2E81-2F2Y	Approved	[3]
Ancrod	DMK2Y4V	Blood forming organ disorder	JB64.1	Phase 3	[4]
3K3A-APC	DMTLR6Y	Cerebrovascular ischaemia	8B1Z	Phase 2	[5]
RPR-120844	DM1V0MD	Discovery agent	N.A.	Investigative	[6]
RPR-118071	DM61VHF	Discovery agent	N.A.	Investigative	[6]
PMID24418773C37	DMG4NQV	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vitamin K-dependent protein C (PROC)	TTZUXYS	PROC_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026237)
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2396).
3	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
4	Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology. 1989 Dec;71(6):870-7.
5	Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr Pharm Des. 2012;18(27):4215-22.
6	Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa. J Med Chem. 1999 Sep 9;42(18):3557-71.
7	Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia. Bioorg Med Chem Lett. 2014 Feb 1;24(3):821-7.